489 related articles for article (PubMed ID: 12923179)
1. Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function.
Tofaris GK; Razzaq A; Ghetti B; Lilley KS; Spillantini MG
J Biol Chem; 2003 Nov; 278(45):44405-11. PubMed ID: 12923179
[TBL] [Abstract][Full Text] [Related]
2. Parkinson's disease transgenic mitochondrial cybrids generate Lewy inclusion bodies.
Trimmer PA; Borland MK; Keeney PM; Bennett JP; Parker WD
J Neurochem; 2004 Feb; 88(4):800-12. PubMed ID: 14756800
[TBL] [Abstract][Full Text] [Related]
3. Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons.
McLean PJ; Kawamata H; Hyman BT
Neuroscience; 2001; 104(3):901-12. PubMed ID: 11440819
[TBL] [Abstract][Full Text] [Related]
4. Alpha-synuclein has an altered conformation and shows a tight intermolecular interaction with ubiquitin in Lewy bodies.
Sharma N; McLean PJ; Kawamata H; Irizarry MC; Hyman BT
Acta Neuropathol; 2001 Oct; 102(4):329-34. PubMed ID: 11603807
[TBL] [Abstract][Full Text] [Related]
5. alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome.
Tofaris GK; Layfield R; Spillantini MG
FEBS Lett; 2001 Nov; 509(1):22-6. PubMed ID: 11734199
[TBL] [Abstract][Full Text] [Related]
6. UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease.
Ardley HC; Scott GB; Rose SA; Tan NG; Robinson PA
J Neurochem; 2004 Jul; 90(2):379-91. PubMed ID: 15228595
[TBL] [Abstract][Full Text] [Related]
7. [Recent neuropathology of parkinsonian syndromes].
Duyckaerts C; Verny M; Hauw JJ
Rev Neurol (Paris); 2003 May; 159(5 Pt 2):3S11-8. PubMed ID: 12773883
[TBL] [Abstract][Full Text] [Related]
8. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies.
Spillantini MG; Crowther RA; Jakes R; Hasegawa M; Goedert M
Proc Natl Acad Sci U S A; 1998 May; 95(11):6469-73. PubMed ID: 9600990
[TBL] [Abstract][Full Text] [Related]
9. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies.
Spillantini MG; Crowther RA; Jakes R; Cairns NJ; Lantos PL; Goedert M
Neurosci Lett; 1998 Jul; 251(3):205-8. PubMed ID: 9726379
[TBL] [Abstract][Full Text] [Related]
10. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies.
Baba M; Nakajo S; Tu PH; Tomita T; Nakaya K; Lee VM; Trojanowski JQ; Iwatsubo T
Am J Pathol; 1998 Apr; 152(4):879-84. PubMed ID: 9546347
[TBL] [Abstract][Full Text] [Related]
11. Proteasome mediates dopaminergic neuronal degeneration, and its inhibition causes alpha-synuclein inclusions.
Sawada H; Kohno R; Kihara T; Izumi Y; Sakka N; Ibi M; Nakanishi M; Nakamizo T; Yamakawa K; Shibasaki H; Yamamoto N; Akaike A; Inden M; Kitamura Y; Taniguchi T; Shimohama S
J Biol Chem; 2004 Mar; 279(11):10710-9. PubMed ID: 14672949
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease.
Shimura H; Schlossmacher MG; Hattori N; Frosch MP; Trockenbacher A; Schneider R; Mizuno Y; Kosik KS; Selkoe DJ
Science; 2001 Jul; 293(5528):263-9. PubMed ID: 11431533
[TBL] [Abstract][Full Text] [Related]
13. Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies.
Junn E; Ronchetti RD; Quezado MM; Kim SY; Mouradian MM
Proc Natl Acad Sci U S A; 2003 Feb; 100(4):2047-52. PubMed ID: 12576551
[TBL] [Abstract][Full Text] [Related]
14. Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry.
Braak H; Sandmann-Keil D; Gai W; Braak E
Neurosci Lett; 1999 Apr; 265(1):67-9. PubMed ID: 10327208
[TBL] [Abstract][Full Text] [Related]
15. Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells.
Rideout HJ; Larsen KE; Sulzer D; Stefanis L
J Neurochem; 2001 Aug; 78(4):899-908. PubMed ID: 11520910
[TBL] [Abstract][Full Text] [Related]
16. Cellular co-localization of phosphorylated tau- and NACP/alpha-synuclein-epitopes in lewy bodies in sporadic Parkinson's disease and in dementia with Lewy bodies.
Arima K; Hirai S; Sunohara N; Aoto K; Izumiyama Y; Uéda K; Ikeda K; Kawai M
Brain Res; 1999 Oct; 843(1-2):53-61. PubMed ID: 10528110
[TBL] [Abstract][Full Text] [Related]
17. Alpha synuclein in neurodegenerative disorders: murderer or accomplice?
Mezey E; Dehejia A; Harta G; Papp MI; Polymeropoulos MH; Brownstein MJ
Nat Med; 1998 Jul; 4(7):755-7. PubMed ID: 9662355
[No Abstract] [Full Text] [Related]
18. Cell cycle aberrations by alpha-synuclein over-expression and cyclin B immunoreactivity in Lewy bodies.
Lee SS; Kim YM; Junn E; Lee G; Park KH; Tanaka M; Ronchetti RD; Quezado MM; Mouradian MM
Neurobiol Aging; 2003 Sep; 24(5):687-96. PubMed ID: 12885576
[TBL] [Abstract][Full Text] [Related]
19. In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies.
Gai WP; Yuan HX; Li XQ; Power JT; Blumbergs PC; Jensen PH
Exp Neurol; 2000 Dec; 166(2):324-33. PubMed ID: 11085897
[TBL] [Abstract][Full Text] [Related]
20. Ubiquitin-proteasome system and Parkinson's diseases.
Betarbet R; Sherer TB; Greenamyre JT
Exp Neurol; 2005 Feb; 191 Suppl 1():S17-27. PubMed ID: 15629758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
